The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

2016-08-15 09:39:13 | BioPortfolio

Published on BioPortfolio: 2016-08-15T09:39:13-0400

Clinical Trials [125 Associated Clinical Trials listed on BioPortfolio]

Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical

The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonge...

Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma

The role of angiogenesis has been less clear in lymphoma than in solid tumors, in part related to the heterogeneity of disease and technical issues. In addition to vascular endothelial gro...

Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-Small Cell Lung Cancer (NSCLC)

To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combi...

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)

This single arm study will assess the safety and efficacy of Endostar combined with chemotherapy (Gemcitabine plus Platinum-based chemotherapy) followed by Endostar maintenance therapy in ...

PubMed Articles [726 Associated PubMed Articles listed on BioPortfolio]

Angiogenic role of miR-20a in breast cancer.

Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs ...

Sirtuin 3 Deficiency Accelerates Hypertensive Cardiac Remodeling by Impairing Angiogenesis.

Emerging evidence indicates that impaired angiogenesis may contribute to hypertension-induced cardiac remodeling. The nicotinamide adenine dinucleotide-dependent deacetylase Sirtuin 3 (SIRT3) has the ...

Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.

Angiogenesis inhibitors are important for cancer therapy, but clinically approved anti-angiogenic agents have shown only modest efficacy and can compromise wound healing. This necessitates the develop...

The Mechanism and Potential Targets Of Class II HDACs in Angiogenesis.

Angiogenesis refers to the new blood vessels deriving from the existing blood vessels, and it's a complex regulatory process. Angiogenesis is associated with the normal development of the body and tum...

Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.

Epithelial ovarian cancer (EOC) is the leading cause of death from gynaecologic malignancies and has a poor prognosis due to metastasis. Drugs targeting the angiogenesis pathway significantly improve ...

Medical and Biotech [MESH] Definitions

Agents that induce or stimulate the PHYSIOLOGIC ANGIOGENESIS process. This is caused by a number of ANGIOGENIC PROTEINS.

Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.

Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Proteins that specifically inhibit the growth of new blood vessels (ANGIOGENESIS, PHYSIOLOGIC).

More From BioPortfolio on "The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients"

Quick Search


Searches Linking to this Trial